STERIS
A global medical-technology company providing sterilization, infection-prevention, surgical, and healthcare-support solutions.
Last updated August 21, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
STERIS plc is a medical-technology company whose products and services are designed to reduce infection risk, support sterile processing, and improve the safety and efficiency of surgical and procedural care. Its principal customers include hospitals, ambulatory surgery centers, endoscopy providers, dental and dialysis practices, pharmaceutical manufacturers, biotechnology companies, and other life-sciences organizations. The company combines capital equipment, consumable products, reusable surgical instruments, repair and maintenance services, outsourced reprocessing, and procedural support rather than operating solely as a conventional device manufacturer. The business began in Ohio in August 1985 under the name Innovative Medical Technologies. It developed around healthcare sterilization and infection-control needs and subsequently expanded into operating-room products, endoscopy, instrument management, equipment service, and life-sciences manufacturing support. Acquisitions have been a central part of that development. Among the most important were US Endoscopy, Integrated Medical Systems International, Synergy Health, Key Surgical, and Cantel Medical Corporation. These transactions broadened STERIS from a primarily equipment-oriented supplier into a diversified provider serving multiple stages of the clinical and industrial sterilization workflow. STERIS's portfolio includes large sterilizers and related sterile-processing equipment sold under established brands such as AMSCO, low-temperature sterilization systems including V-PRO, surgical and endoscopy products, instrument-tracking and management solutions, and services for maintaining, repairing, and reprocessing medical devices. In life sciences, the company supplies sterilization and contamination-control equipment and services used by pharmaceutical and biotechnology manufacturers. Its service activities can place STERIS directly inside customer facilities or production processes, creating recurring relationships alongside equipment sales. The company has also undergone several changes in legal domicile. It was incorporated in the United States at its formation, moved its legal registration to the United Kingdom in connection with the 2014 acquisition of Synergy Health, and announced a further move of its legal headquarters to Ireland in 2018. Its operational headquarters remains in Mentor, Ohio. This separation between operational management and legal domicile has been an important feature of the company's corporate history, particularly because the 2014 transaction was widely discussed in the context of corporate tax inversions. STERIS is listed on the New York Stock Exchange under the symbol STE and is included in the S&P 500 Index. The company operates internationally, with the United States remaining a major market while its acquired businesses and commercial infrastructure give it a substantial presence across Europe and other regions. During the COVID-19 pandemic, the company received U.S. Food and Drug Administration emergency authorization for a system intended to sterilize certain N95 respirators, demonstrating the relevance of its sterilization technology to a public-health supply shortage. As of 2024, Daniel A. Carestio was identified as the company's president and chief executive officer.
History
STERIS traces its origins to August 1985, when it was established in Ohio as Innovative Medical Technologies. The company entered the market around the need for dependable sterilization and infection-prevention systems in healthcare. Over time, its activities grew beyond sterilizer equipment to include sterile-processing supplies, surgical and endoscopy products, equipment maintenance, device repair, and services supporting hospitals and other care providers. A major phase of expansion occurred through acquisitions. In 2012, STERIS bought US Endoscopy for approximately $270 million and also acquired Spectrum Surgical Instruments Corp. and Total Repair Express for a combined amount reported at about $110 million. These transactions increased its exposure to endoscopy, surgical instruments, and repair services. In April 2014, it announced the acquisition of Integrated Medical Systems International for an indicated value of approximately $175 million before tax benefits. It also acquired Life Systems, based in Chesterfield, Missouri, during the same general period. The company's most consequential corporate transaction came in 2014, when STERIS agreed to acquire UK-based Synergy Health for approximately $1.9 billion. The deal was structured with a change in legal domicile from the United States to the United Kingdom. It became a prominent example of a corporate tax inversion and attracted attention because it followed new U.S. policy measures intended to discourage transactions in which American companies moved their legal domicile to reduce exposure to U.S. corporate taxation. The transaction also substantially strengthened STERIS's international healthcare-services operations. In June 2015, STERIS announced the acquisitions of General Econopak and Black Diamond Video. General Econopak was reported at approximately $175 million and Black Diamond Video at approximately $51 million. These deals added further products and capabilities connected with healthcare and procedural environments. By 2018, company accounts reported global revenue above $2.6 billion and employment of approximately 12,000 people; the United States healthcare system represented the largest portion of reported revenue. STERIS announced in November 2018 that it intended to move its legal headquarters again, this time from the United Kingdom to Ireland. The company continued to manage its operations from Mentor, Ohio, while Dublin became its legal registration location. The move followed the earlier UK redomiciliation and was discussed in relation to the company's corporate tax structure. The COVID-19 emergency highlighted STERIS's sterilization expertise. In April 2020, the U.S. Food and Drug Administration issued emergency use authorization for a STERIS system designed to sterilize certain N95 respirators. The system was intended to help address shortages of personal protective equipment during the pandemic. Later in 2020, STERIS acquired Key Surgical, a global supplier serving sterile processing, operating rooms, and endoscopy. In June 2021, STERIS acquired Cantel Medical Corporation. Cantel brought infection-prevention products and services in endoscopy, dental, and dialysis, complementing STERIS's existing equipment, consumables, and service operations. Through these acquisitions, the company developed a broad model spanning capital equipment, single-use and reusable products, technical services, outsourced reprocessing, and life-sciences manufacturing support. STERIS remains operationally headquartered in Mentor, Ohio, while legally registered in Dublin. It trades on the New York Stock Exchange under the symbol STE and is included in the S&P 500 Index. As of 2024, Daniel A. Carestio was identified as president and chief executive officer.
- 2021
Cantel Medical acquisition
[1]STERIS acquired Cantel Medical Corporation, adding infection-prevention activities in endoscopy, dental, and dialysis.
- 2020
Emergency authorization for N95 sterilization
[1]The FDA authorized emergency use of a STERIS system for sterilizing certain N95 respirators during the COVID-19 response.
- 2020
Key Surgical acquisition
[1]STERIS acquired Key Surgical, expanding its sterile-processing, operating-room, and endoscopy product portfolio.
- 2018
Legal headquarters move to Ireland announced
[1]STERIS announced a further legal redomiciliation from the United Kingdom to Ireland.
- 2015
General Econopak and Black Diamond Video acquisitions
[1]STERIS announced acquisitions intended to broaden its healthcare and procedural-product capabilities.
- 2014
Integrated Medical Systems International acquisition
[1]The company announced the acquisition of Integrated Medical Systems International and subsequently acquired Life Systems.
- 2014
Synergy Health transaction and UK redomiciliation
[1]STERIS announced its approximately $1.9 billion acquisition of Synergy Health, resulting in a legal move to the United Kingdom.
- 2012
Expansion into endoscopy and instrument services
[1]STERIS acquired US Endoscopy, Spectrum Surgical Instruments, and Total Repair Express.
- 1985
Company founded as Innovative Medical Technologies
[1]STERIS originated in Ohio in August 1985 under the name Innovative Medical Technologies.
Products and positioning
A vertically integrated infection-prevention and procedural-care partner serving healthcare providers and life-sciences manufacturers through equipment, consumables, instruments, reprocessing, and technical services.
Sterilization equipment
AMSCO sterilizers
The AMSCO family includes sterilization and sterile-processing equipment used by healthcare institutions. These systems are designed for the preparation and sterilization of reusable medical instruments and related loads in hospital and procedural environments. They form part of STERIS's capital-equipment offering and are typically supported by installation, maintenance, consumables, and technical-service programs.
Low-temperature sterilization
V-PRO low-temperature sterilization systems
V-PRO systems provide low-temperature sterilization for compatible medical devices and instruments that may not be suitable for conventional high-temperature steam processing. The line supports sterile-processing departments seeking an alternative method for heat-sensitive devices and is part of STERIS's broader infection-prevention platform.
Surgical products and services
Surgical Solutions
STERIS's Surgical Solutions activities cover products and services used around operating rooms and surgical workflows. The offering includes surgical instruments, procedural supplies, equipment support, and related services intended to help hospitals manage instrument readiness, operating-room efficiency, and infection-prevention requirements.
Endoscopy
US Endoscopy products
US Endoscopy products serve gastrointestinal and other endoscopic procedures. Following STERIS's acquisition of the business, the portfolio became part of the company's endoscopy platform, complementing sterilization equipment and reprocessing services with procedure-specific devices and consumables.
Sterile processing and operating-room supplies · 2020
Key Surgical products
Key Surgical supplies products for sterile-processing departments, operating rooms, and endoscopy settings. Its addition strengthened STERIS's range of instruments, supplies, and workflow products used before, during, and after procedures.
Healthcare services
Healthcare equipment and instrument services
STERIS provides repair, maintenance, reprocessing, and other technical services for healthcare equipment and reusable medical devices. These services extend beyond product sales and can include support delivered at customer facilities, helping healthcare organizations maintain equipment availability and instrument readiness.
Marketing campaigns
- 2020N95 respirator sterilization response
United States
During the COVID-19 pandemic, STERIS promoted and supplied a sterilization approach intended to help address shortages of N95 respirators. The initiative was supported by FDA emergency use authorization for the relevant system.
Outcome. Emergency use authorization was granted for the system.
Brand decisions
2021
Acquire Cantel Medical CorporationM&ABackground
STERIS sought to broaden its infection-prevention platform and strengthen its position in procedure-specific healthcare markets.
Action taken
The company acquired Cantel Medical Corporation, a provider of infection-prevention products and services.
Aftermath
STERIS expanded its endoscopy, dental, and dialysis offerings and added Cantel's related services to its portfolio.
2020
Introduce an emergency N95 respirator sterilization systemProduct launchBackground
The COVID-19 pandemic created severe shortages of personal protective equipment, including N95 respirators.
Action taken
STERIS obtained FDA emergency use authorization for a system intended to sterilize certain N95 respirators.
Aftermath
The authorization enabled the technology to be used as part of efforts to extend the availability of certain respirators during the emergency response.
2018
Move legal headquarters from the United Kingdom to IrelandStrategyBackground
After its 2014 move to the United Kingdom, STERIS determined that a further legal redomiciliation could reduce its corporate tax burden.
Action taken
STERIS announced that its legal headquarters would move to Ireland while operational management remained based in Mentor, Ohio.
Aftermath
The company became legally registered in Dublin and continued to operate internationally from its established business infrastructure.
2014
Acquire Synergy Health and redomicile to the United KingdomM&ABackground
STERIS sought to expand its international healthcare-services platform through the acquisition of UK-based Synergy Health.
Action taken
The company announced an approximately $1.9 billion acquisition and changed its legal domicile to the United Kingdom.
Aftermath
The transaction made STERIS a prominent example in public discussion of U.S. corporate tax inversions and increased its international operating footprint.
Announced transaction value. Approximately US$1.9 billion (2014)
Recent events
STERIS reports fiscal 2022 first-quarter results[3]
Reported:
STERIS reported fiscal 2022 first-quarter financial results, including revenue growth and segment results.
STERIS raises fiscal 2022 outlook[3]
Reported:
STERIS raised its fiscal 2022 revenue, organic growth and adjusted earnings expectations.
STERIS announces CEO succession plan[4]
Reported:
STERIS announced that Walt Rosebrough intends to step down as CEO on July 29, 2021, and that Chief Operating Officer Dan Carestio will succeed him as President and CEO on that date.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/steris · Editorial policy · How profiles are compiled